Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528983 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 133
- Enrollment target
NCT00528983 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 133 participants.
The verdict
NCT00528983, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 133 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a tablet form of azacitidine that taken by mouth is safe. This Phase I study will also look at different doses and different treatment schedules in order to better understand the effects (positive and negative) of oral azacitidine on the body and on the disease MDS, AML and CMML.
Interventions
- DRUG Oral Azacitidine
- DRUG Subcutaneous (SC) Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2007-09-11 |
| Est. Completion | 2016-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528983
The ClinicalTrials.gov registry entry for NCT00528983 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oral Azacitidine is the first listed.
NCT00528983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00528983 about?
NCT00528983 is a clinical study titled "Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia". The purpose of this study is to determine whether a tablet form of azacitidine that taken by mouth is safe. This Phase I study will also look at different doses and different treatment schedules in order to better understand the effects (positive and negative) of oral azacitidine on the body and on ...
What is the current status of trial NCT00528983?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 133 participants. The study started on 2007-09-11. Estimated completion is 2016-04-05.
What interventions are being tested in trial NCT00528983?
The interventions under investigation include: Oral Azacitidine (DRUG), Subcutaneous (SC) Azacitidine (DRUG).
Who is sponsoring clinical trial NCT00528983?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.